BE-43547 has in vivo anti-tumor activity in mouse tumor models

Published: 4 August 2018| Version 1 | DOI: 10.17632/d5m9my4hmb.1
Kristian Mark Jacobsen,


Tumor volume and body weight: Tumor volume in mice bearing C3H mammary adenocarcinoma subcutaneous foot tumors, treated with vehicle (DMSO) or 5 mg/kg of BE-43547 for 7 consecutive days (indicated by arrows) starting when tumors reached 200 mm3 (day 1). Mice were sacrificed when the maximum allowable tumor volume was reached or when mice showed clear signs of morbidity, this was the case for two mice in the treated group. Body weight of the same mice can also be found in the Excel-file. 18FDG and HE staining of SiHa tumor slices: Visual comparison of intratumoral glycolytic activity (18FDG) and necrosis (HE) in representative SiHa tumor slices after treatment with a single IP injection of BE-43547 congeners at 10 mg/kg followed by one resting day, and then one IP injection on each 4 consecutive days at 5 mg/kg.One day after the last treatment, mice were injected IP with the glucose tracer analogue 18FDG. One hour later mice were sacrificed and tumors were removed and snap-frozen in pre-cooled isopentane. Subsequently, multiple 10 µm tumor sections were prepared using a cryostat, and analyzed for intratumoral glucose retention (FDG) with digital autoradiography. Following autoradiographic analysis, tissue sections were hematoxylin and eosin (H&E) stained for visualization of necrosis and digitalized using a Hamamatsu NanoZoomer slide scanner (Hamamatsu Photonics, Shizuoka, Japan).



Tumor Growth, Xenograft, In Vivo Study